University-Industry Engagement Week

Monash U inks antibody development research deal with Ono Pharmaceutical


By David Schwartz
Published: January 23rd, 2023

Japan’s Ono Pharmaceutical and Australia’s Monash University have entered an option and research collaboration deal for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs).

The collaboration is focused on developing anti-GPCR antibodies aimed at new treatments for autoimmune and inflammatory diseases. Under the deal terms, the Biomedicine Discovery Institute of Monash University will lead the antibody discovery campaign. Ono Pharmaceutical will have exclusive global rights for the development and commercialization of some existing antibodies developed by Monash University, along with any antibodies developed as a result of the collaboration.

“We appreciate Monash University’s sophisticated technologies for antibody discovery which enables the creation of therapeutic antibodies using monoclonal antibodies against GPCR,” said Toichi Takino, senior executive officer and executive director of Ono Pharmaceutical Discovery & Research.

Monash will receive an upfront payment in addition to research funding that will be provided during the option period. The university will also receive milestone payments on clinical development and sales progress, along with royalties based on net sales of the products in the future if the option is exercised.

Monash University Biomedicine Discovery Institute senior research fellow Dr Remy Robert said: “We are excited to partner with Ono Pharmaceutical and combine our expertise in anti-GPCR antibody discovery with Ono’s exceptional capabilities in drug development.

“We look forward to working with Ono Pharmaceutical to accelerate treatments across a variety of diseases.”

Source: Pharmaceutical Technology

Posted under: University-Industry Engagement Week